Literature DB >> 8954998

Fas/APO-1-mediated apoptosis of human renal cell carcinoma.

N Nonomura1, T Miki, M Yokoyama, T Imazu, T Takada, S Takeuchi, N Kanno, K Nishimura, Y Kojima, A Okuyama.   

Abstract

We have investigated the Fas-mediated apoptosis of cultured human renal cell carcinoma OUR-10. OUR-10 cells express Fas antigen on their cell surface and showed apoptotic cell death by stimulation with anti-Fas agonistic antibody. Cell proliferation of OUR-10 was reduced to 62% by the addition of anti-Fas antibody. The cytotoxic effect of anti-Fas antibody on OUR-10 was augmented by the pretreatment of these cells with interferon-gamma, not with interferon-alpha or with interleukin-2. Flow cytometry demonstrated that preculture of Our-10 cells with interferon-gamma increased the cell surface Fas antigen. Immunohistochemical analysis of resected tissues from the patients with renal cancer revealed stronger expression of Fas antigen on the surface of cancer cells than that of normal cells. These data suggest that Fas may be one of the possible targets for a novel approach to human kidney cancer, and the efficiency of this Fas-mediated treatment for kidney cancer could be augmented by the treatment with interferon-gamma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8954998     DOI: 10.1006/bbrc.1996.1906

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.

Authors:  U Ramp; M Dejosez; C Mahotka; B Czarnotta; T Kalinski; M Wenzel; I Lorenz; M Müller; P Krammer; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

2.  Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients.

Authors:  M Kimura; Y Tomita; T Imai; T Saito; A Katagiri; T Tanikawa; M Takeda; K Takahashi
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

3.  Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma.

Authors:  R Maruyama; K Yamana; T Itoi; N Hara; V Bilim; T Nishiyama; K Takahashi; Y Tomita
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

4.  Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma.

Authors:  Hitoshi Takayama; Tetsuya Takakuwa; Yuichi Tsujimoto; Norio Nonomura; Akihiko Okuyama; Katsuyuki Aozasa
Journal:  Jpn J Cancer Res       Date:  2002-11

5.  Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.

Authors:  J D Kelly; J Dai; P Eschwege; J S Goldberg; B P Duggan; K E Williamson; N H Bander; D M Nanus
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.